BioTuesdays

Category - Markets

Markets

Roth starts Oxurion at buy; PT €9

Roth Capital Partners initiated coverage of Oxurion (Euronext Brussels:OXUR) with a “buy” rating and price target of €9. The stock was recently quoted at €2.41. “Our investment thesis is based on our understanding...

December 23, 2019
Ocugen
Markets

HCW starts Ocugen at buy; PT $1.25

H.C. Wainwright launched coverage of Ocugen (NASDAQ:OCGN) with a “buy” rating and price target of $1.25. The stock closed at 36 cents on Dec. 19. Ocugen is developing therapies for rare and underserved eye diseases and...

December 20, 2019
Mesoblast Logo
Markets

Dawson James starts Mesoblast at buy; PT $14

Dawson James Securities initiated coverage of Mesoblast (NASDAQ:MESO; ASX:MSB) with a “buy” rating and $14 price target. The stock closed at $7.42 on Dec. 18. Mesoblast is using its proprietary technology platform to...

December 19, 2019
X4 Pharma
Markets

Roth starts X4 Pharma at buy; PT $20

Roth Capital Partners launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $20 price target. The stock closed at $11 on Dec. 17. Analyst Zegbeh Jallah writes that her investment thesis is based...

December 18, 2019
Aduro Biotech
Markets

Analysts downgrade and lower PTs for Aduro Biotech

William Blair downgraded Aduro Biotech (NASDAQ:ADRO) to “market perform” from “outperform” and H.C. Wainwright cut its price target for Aduro after Novartis removed Aduro’s intratumoral STING agonist, ADU-S100, from its...

December 18, 2019
Diffusion Pharma Logo
Markets

HCW cuts Diffusion Pharma PT to $3.50 on dilution

H.C. Wainwright lowered its price target for Diffusion Pharmaceuticals (NASDAQ:DFFN) to $3.50 from $10, reflecting dilution from two recent financings. The stock closed at 41 cents on Dec. 17. Analyst Swayampakula...

December 18, 2019
Adamas Pharmaceuticals Logo
Markets

SVB Leerink halves Adamas Pharma PT to $6

SVB Leerink lowered its price target for Adamas Pharmaceuticals (NASDAQ:ADMS) to $6 from $13, saying the mixed Phase 3 INROADS data are not good enough. In afternoon trading on Dec. 17, the stock was quoted at $4.15...

December 17, 2019
Wave Life Sciences
Markets

SVB Leerink ups Wave Life Sciences PT to $46 from $40

SVB Leerink raised its price target for Wave Life Sciences (NASDAQ:WVE) to $46 from $40 after the FDA approved Sarepta Therapeutics’ (NASDAQ:SRPT) golodirsen for the treatment of Duchenne muscular dystrophy (DMD) in...

December 13, 2019